We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: hepatocellular carcinoma
MedXY News
EnglishTag

hepatocellular carcinoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial
newsatezolizumabbevacizumab

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

By MedXY|Oct 28, 2025

A recent phase II trial demonstrates lenvatinib’s efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming
newsAlcoholHBV

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming

By MedXY|Oct 27, 2025

This article explores how alcohol consumption worsens HBV-induced hepatocellular carcinoma by promoting ER stress and lipid metabolic disturbances, highlighting potential therapeutic targets like LPLA2 and BMP.

Microbial Metabolism Dysfunction and Its Impact on Liver Injury After TACE in Hepatocellular Carcinoma
Gastroenterologygut microbiotahepatocellular carcinoma

Microbial Metabolism Dysfunction and Its Impact on Liver Injury After TACE in Hepatocellular Carcinoma

By MedXY|Oct 27, 2025

This review explores how gut microbiota disturbances, especially L. reuteri and its metabolite ILA, influence post-TACE liver injury and prognosis in HCC patients, highlighting potential microbiota-targeted therapies.

Comparative Risks of MASLD and MetALD: Insights from a Comprehensive Meta-Analysis on Hepatic and Extrahepatic Outcomes
Gastroenterologyhepatocellular carcinomaliver-related events

Comparative Risks of MASLD and MetALD: Insights from a Comprehensive Meta-Analysis on Hepatic and Extrahepatic Outcomes

By MedXY|Oct 19, 2025

This meta-analysis reveals that MetALD confers higher risks of liver-related events, hepatocellular carcinoma, and extrahepatic cancers compared to MASLD, while mortality and cardiovascular risks are similar, emphasizing tailored clinical a

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score
Gastroenterologyhepatocellular carcinomaMASLD

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score

By MedXY|Oct 9, 2025

Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful m

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes
AIhepatocellular carcinomaimmunotherapy

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes

By MedXY|Oct 9, 2025

Integrated radiomic-clinical machine learning models outperform traditional clinical biomarkers in predicting survival and treatment response in unresectable hepatocellular carcinoma patients undergoing atezolizumab plus bevacizumab therapy

Optimizing Treatment Selection for Hepatocellular Carcinoma: Machine Learning Guidance in Choosing Liver Transplantation versus Surgical Resection
General Surgeryhepatocellular carcinomaliver transplantation

Optimizing Treatment Selection for Hepatocellular Carcinoma: Machine Learning Guidance in Choosing Liver Transplantation versus Surgical Resection

By MedXY|Oct 9, 2025

A machine learning model accurately stratifies patients with hepatocellular carcinoma to guide individualized selection between liver transplantation and surgical resection, improving survival outcomes while addressing donor scarcity and pa

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma
Clinical UpdatesHBVhepatocellular carcinoma

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY|Oct 6, 2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatment

Targeting Oxytocin Receptor: A Novel Strategy Against Hepatocellular Carcinoma Using Atosiban
newsAtosibanhepatocellular carcinoma

Targeting Oxytocin Receptor: A Novel Strategy Against Hepatocellular Carcinoma Using Atosiban

By MedXY|Oct 5, 2025

Recent research identifies the oxytocin receptor (OXTR) as a critical driver of liver cancer via Hippo/YAP signaling. The FDA-approved tocolytic drug Atosiban shows promise in blocking this pathway, offering new therapeutic avenues in hepat

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials
Clinical Updatesclinical trialhepatocellular carcinoma

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

By MedXY|Oct 1, 2025

The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials
Clinical Updatesclinical trialhepatocellular carcinoma

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

By MedXY|Oct 1, 2025

The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial
Clinical Updatesbevacizumabhepatocellular carcinoma

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY|Oct 1, 2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.

Prev
3 / 3
123
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities